Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G.

Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.

PMID:
22995650
2.

Aprepitant for pruritus: drug-drug interactions matter.

Mir O, Coriat R.

Lancet Oncol. 2012 Oct;13(10):964-5. doi: 10.1016/S1470-2045(12)70397-2. Epub 2012 Sep 18. No abstract available.

PMID:
22995652
3.

Paraneoplastic pruritus presenting with Hodgkin's lymphoma: a case report.

Villafranca JJ, Siles MG, Casanova M, Goitia BT, Domínguez AR.

J Med Case Rep. 2014 Sep 8;8:300. doi: 10.1186/1752-1947-8-300.

4.

Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.

Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA.

PLoS One. 2010 Jun 4;5(6):e10968. doi: 10.1371/journal.pone.0010968.

5.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

7.

Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant.

Jiménez Gallo D, Albarrán Planelles C, Linares Barrios M, Fernández Anguita MJ, Márquez Enríquez J, Rodríguez Mateos ME.

Dermatol Ther. 2014 May-Jun;27(3):178-82. doi: 10.1111/dth.12113. Epub 2013 Dec 2.

PMID:
24517320
8.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.

Cancer. 2003 May 1;97(9):2290-300.

9.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
10.

A comparative analysis of cetirizine, gabapentin and their combination in the relief of post-burn pruritus.

Ahuja RB, Gupta R, Gupta G, Shrivastava P.

Burns. 2011 Mar;37(2):203-7. doi: 10.1016/j.burns.2010.06.004. Epub 2010 Nov 13.

PMID:
21075537
12.

Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin.

Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K.

Cancer Sci. 2010 Nov;101(11):2455-61. doi: 10.1111/j.1349-7006.2010.01689.x.

13.

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE.

Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.

PMID:
22277837
14.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
15.

Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.

Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.

Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111/j.1445-5994.2011.02637.x.

PMID:
22141732
16.

Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation.

Uchida M, Ikesue H, Miyamoto T, Kato K, Suetsugu K, Ichinose K, Hiraiwa H, Sakurai A, Takenaka K, Muta T, Iwasaki H, Teshima T, Shiratsuchi M, Egashira N, Akashi K, Oishi R.

Biol Pharm Bull. 2013;36(5):819-24.

17.

A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.

Wong SF, Lindgren A, Mummaneni M, Byun T, Vasko C, Arenos R, Alexson E, Osann K.

J Support Oncol. 2010 Sep-Oct;8(5):202-8.

PMID:
21086877
18.

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.

Hu Z, Cheng Y, Zhang H, Zhou C, Han B, Zhang Y, Huang C, Chang J, Song X, Liang J, Liang H, Bai C, Yu S, Chen J, Wang J, Pan H, Chitkara DK, Hille DA, Zhang L.

Support Care Cancer. 2014 Apr;22(4):979-87. doi: 10.1007/s00520-013-2043-9. Epub 2013 Nov 26.

PMID:
24276953
19.

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.

de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ.

J Clin Oncol. 2003 Nov 15;21(22):4105-11. Epub 2003 Oct 14.

PMID:
14559891
20.

Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.

Osorio-Sanchez JA, Karapetis C, Koczwara B.

Intern Med J. 2007 Apr;37(4):247-50.

PMID:
17388865

Supplemental Content

Support Center